Related Experiment Video
Updated: Feb 11, 2026

Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
Phosphodiesterase-5 inhibition potentiates cerebrovascular reactivity in chronic traumatic brain injury
Kimbra Kenney1, Franck Amyot1, Carol Moore1
1Department of Neurology Uniformed Services University of the Health Sciences Bethesda Maryland.
Background:
Traumatic cerebrovascular injury (TCVI), a common consequence of traumatic brain injury (TBI), presents an attractive therapeutic target. Because phosphodiesterase-5 (PDE5) inhibitors potentiate the action of nitric oxide (NO) produced by endothelial cells, they are candidate therapies for TCVI. This study aims to: (1) measure cerebral blood flow (CBF), cerebrovascular reactivity (CVR), and change in CVR after a single dose of sildenafil (ΔCVR) in chronic TBI compared to uninjured controls; (2) examine the safety and tolerability of 8-week sildenafil administration in chronic symptomatic moderate/severe TBI patients; and as an exploratory aim, (3) assess the effect of an 8-week course of sildenafil on chronic TBI symptoms.
Methods:
Forty-six subjects (31 chronic TBI, 15 matched healthy volunteers) were enrolled. Baseline CBF and CVR before and after administration of sildenafil were measured. Symptomatic TBI subjects then completed an 8-week double-blind, placebo-controlled, crossover trial of sildenafil. A neuropsychological battery and neurobehavioral symptom questionnaires were administered at each study visit.
Results:
After a single dose of sildenafil, TBI subjects showed a significant increase in global CVR compared to healthy controls (P < 0.001, d = 0.9). Post-sildenafil CVR maps showed near-normalization of CVR in many regions where baseline CVR was low, predominantly within areas without structural abnormalities. Sildenafil was well tolerated. Clinical Global Impression (CGI) scale showed a trend toward clinical improvement while on sildenafil treatment.
Findings:
Single-dose sildenafil improves regional CVR deficits in chronic TBI patients. CVR and ΔCVR are potential predictive and pharmacodynamic biomarkers of PDE5 inhibitor therapy for TCVI. Sildenafil is a potential therapy for TCVI.
Insights
Sildenafil treatment improved cerebrovascular reactivity (CVR) in patients with chronic traumatic brain injury (TBI). This phosphodiesterase-5 inhibitor shows promise for treating traumatic cerebrovascular injury (TCVI).
Area of Science:
- Neuroscience
- Vascular Biology
- Pharmacology
Background:
- Traumatic cerebrovascular injury (TCVI) is a significant complication of traumatic brain injury (TBI).
- Phosphodiesterase-5 (PDE5) inhibitors, like sildenafil, enhance nitric oxide (NO) signaling and are potential treatments for TCVI.
- Understanding the impact of PDE5 inhibitors on cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) in TBI is crucial.
Purpose of the Study:
- To measure CBF, CVR, and the change in CVR (ΔCVR) after a single sildenafil dose in chronic TBI patients versus controls.
- To assess the safety and tolerability of 8-week sildenafil administration in symptomatic TBI patients.
- To explore the effect of 8-week sildenafil treatment on chronic TBI symptoms.
Main Methods:
- Forty-six participants (31 with chronic TBI, 15 healthy controls) were enrolled.
- Baseline CBF and CVR were measured before and after sildenafil administration.
- A double-blind, placebo-controlled, crossover trial of 8-week sildenafil was conducted in symptomatic TBI patients, with neuropsychological and symptom assessments.
Main Results:
- A single dose of sildenafil significantly increased global CVR in TBI subjects compared to controls (P < 0.001).
- Post-sildenafil CVR maps indicated near-normalization in regions with previously low CVR, particularly in structurally intact areas.
- Sildenafil was well-tolerated, and a trend toward clinical improvement was observed on the Clinical Global Impression scale.
Conclusions:
- Single-dose sildenafil effectively improves regional CVR deficits in chronic TBI patients.
- CVR and ΔCVR may serve as predictive and pharmacodynamic biomarkers for PDE5 inhibitor therapy in TCVI.
- Sildenafil demonstrates potential as a therapeutic agent for TCVI.
Related Concept Videos
Feedback Inhibition
5-Number Summary
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Traumatic Memory
Cross-reactivity
Reactivity of Enols

